Q-omics provides the consensus-scored IL11RA profile across patient tissues and cancer cell-line models. IL11RA expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, IL11RA is differentially expressed in 15, with the highest sampling consensus in LUAD. Additionally, IL11RA RNA expression shows 18,768 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, LUAD, and ACC as cancer lineages where IL11RA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL11RA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL11RA survival associations across molecular data types. IL11RA RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL11RA RNA expression–survival associations across cancer types. High IL11RA expression shows unfavorable associations in ACC and UCEC, but favorable associations in UVM, PAAD, LUAD and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify UVM as the clearest survival context for IL11RA RNA expression.
This table summarizes IL11RA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for IL11RA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL11RA shows lower tumor expression in LUAD, BLCA, LUSC, THCA, KIRC and KICH. The LUAD box plot shows higher IL11RA RNA expression in normal versus tumor tissue (log2 FC = −1.745, t-test p < 0.001).
This table shows molecular features associated with IL11RA in patient tissues and cancer cell lines. In patient samples, IL11RA shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, IL11RA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
